BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 18268286)

  • 21. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
    Schouweiler KE; Karandikar NJ; Holman CJ
    Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
    van Velzen JF; van den Blink D; Bloem AC
    Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
    Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
    Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
    Martín P; Santón A; Bellas C
    Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Measurable disease evaluation in patients with myeloma.
    Roshal M
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101154. PubMed ID: 32139019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
    Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A
    J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Analysis of cell morphology and immunophenotypic characteristics in 47 cases of multiple myeloma].
    Su XD; Lin R; Xu XL; Chen X; Zhan WL; Zheng JP; Fan CL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Feb; 23(1):137-41. PubMed ID: 25687061
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Simplified flow cytometric immunophenotyping panel for multiple myeloma, CD56/CD19/CD138(CD38)/CD45, to differentiate neoplastic myeloma cells from reactive plasma cells.
    Jeong TD; Park CJ; Shim H; Jang S; Chi HS; Yoon DH; Kim DY; Lee JH; Lee JH; Suh C; Lee KH
    Korean J Hematol; 2012 Dec; 47(4):260-6. PubMed ID: 23320004
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiparameter Flow Cytometry Identification of Neoplastic Subclones: A New Biomarker in Monoclonal Gammopathy of Undetermined Significance and Multiple Myeloma.
    Tarín F; López-Castaño F; García-Hernández C; Beneit P; Sarmiento H; Manresa P; Alda O; Villarrubia B; Blanes M; Bernabéu J; Amorós C; Sánchez-Sánchez S; Fernández-Miñano C; De Paz F; Verdú-Belmar J; Marco P; Matutes E
    Acta Haematol; 2019; 141(1):1-6. PubMed ID: 30428459
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-kit receptor (CD117) expression on plasma cells in monoclonal gammopathies.
    Kraj M; Pogłód R; Kopeć-Szlezak J; Sokołowska U; Woźniak J; Kruk B
    Leuk Lymphoma; 2004 Nov; 45(11):2281-9. PubMed ID: 15512818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunophenotypic characterization of normal and abnormal plasma cells in bone marrow of newly diagnosed multiple myeloma patients.
    Awasthi NP; Mishra S; Gupta G; Kumari S; Bajpayee A; Singh P; Husain N
    Indian J Pathol Microbiol; 2023; 66(2):295-300. PubMed ID: 37077071
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry.
    Alaterre E; Raimbault S; Garcia JM; Rème T; Requirand G; Klein B; Moreaux J
    Cytometry B Clin Cytom; 2018 May; 94(3):484-492. PubMed ID: 28865180
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotypic characterization and quantification of neoplastic bone marrow plasma cells by multiparametric flow cytometry and its clinical significance in Korean myeloma patients.
    Cho YU; Park CJ; Park SJ; Chi HS; Jang S; Park SH; Seo EJ; Yoon DH; Lee JH; Suh C
    J Korean Med Sci; 2013 Apr; 28(4):542-9. PubMed ID: 23580331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of CD54, CD229, and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
    Pojero F; Flores-Montero J; Sanoja L; Pérez JJ; Puig N; Paiva B; Bottcher S; van Dongen JJ; Orfao A;
    Cytometry B Clin Cytom; 2016 Jan; 90(1):91-100. PubMed ID: 26130131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of plasma cell myeloma minimal residual disease testing by flow cytometry in an international inter-laboratory study: Is it ready for primetime use?
    Scott SD; Fletcher M; Whitehouse H; Whitby L; Yuan C; Mazzucchelli S; Lin P; de Tute R; Dorwal P; Wallace PK; Tembhare P; Arroz M; Snowden JA; Chantry AD; Barnett D
    Cytometry B Clin Cytom; 2019 May; 96(3):201-208. PubMed ID: 30565840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Bone marrow immunophenotyping for the diagnosis of multiple myeloma: practical aspects].
    Kurtova AV; Sivachenko EB; Utkina LA; Slobodniuk KIu; Stepanova NV; Iakubovich MA; Moiseev SI; Zueva EE
    Klin Lab Diagn; 2008 Jan; (1):17-20. PubMed ID: 18314774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.